Theravance Reports Positive Phase II Results For Chronic Constipation Therapy TD-5108
This article was originally published in The Pink Sheet Daily
Executive Summary
Specificity of the 5-HT4 agonist gives it a better cardiovascular safety profile than withdrawn Novartis product Zelnorm, Theravance VP-Development Kitt says.